Company Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States.
It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.
The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.
Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Country | United States |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 22 |
CEO | John T. Cavan |
Contact Details
Address: 399 Thornall Street, First Floor Edison, New Jersey 08837 United States | |
Phone | 732-902-4000 |
Website | hepionpharma.com |
Stock Details
Ticker Symbol | HEPA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001583771 |
CUSIP Number | 426897104 |
ISIN Number | US4268973025 |
Employer ID | 46-2783806 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
John T. Cavan | Interim Chief Executive Officer and Chief Financial Officer |
Sharen Pyatetskaya | Director of Investor Relations |
Dr. John Z. Sullivan-Bolyai | Part-Time Consultant |
Dr. Stephen A. Harrison FACP, M.D. | Scientific Advisory Board Chair and Consultant Medical Director |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 15, 2024 | EFFECT | Notice of Effectiveness |
Jul 15, 2024 | 424B3 | Prospectus |
Jul 11, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
Jun 25, 2024 | 10-K/A | [Amend] Annual report |
May 21, 2024 | 10-Q | Quarterly Report |
May 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
Apr 16, 2024 | 10-K | Annual Report |
Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
Mar 6, 2024 | 8-K | Current Report |
Feb 20, 2024 | 8-K | Current Report |